{
    "title": "Regeneron profit tanks on zero U.S. sales from COVID drug for second quarter",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11076781/Regeneron-profit-tanks-zero-U-S-sales-COVID-drug-second-quarter.html",
    "date": "2022-08-03",
    "keywords": [
        "year",
        "drug",
        "quarter",
        "profit",
        "antibody",
        "regulator",
        "lack",
        "revenue",
        "dupixent",
        "share",
        "fall",
        "covid19",
        "cocktail",
        "health",
        "use",
        "company",
        "regencov",
        "regeneron",
        "half",
        "effectiveness",
        "omicron",
        "coronavirus",
        "regencovs",
        "fate",
        "phase",
        "sotrovimab",
        "gsk",
        "biotechnology",
        "combo",
        "virus",
        "secondquarter",
        "hit",
        "covid",
        "blockbuster",
        "antiinflammation",
        "sanofi",
        "eye",
        "treatment",
        "eylea",
        "expansion",
        "reporting",
        "roy",
        "bengaluru",
        "editing",
        "shinjini",
        "ganguli"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}